Leukadherin 1|Leukadherin1|agonist of CR3

Leukadherin 1|Leukadherin1|agonist of CR3

Leukadherin-1 is a specific agonist of CR3 and the leukocyte surface integrin CD11b/CD18.

Product Name: Leukadherin-1 |Cat No: DC9953|cas: 344897-95-6|Other Names: Leukadherin 1,Leukadherin1

Leukadherin-1 is a specific agonist of CR3 and the leukocyte surface integrin CD11b/CD18.In vitro: Leukadherin‐1 (LA1) modulates natural killer (NK) cell inflammatory cytokine secretion. The SLE-associated CD11b‐R77H variant does not influence NK cell response to Leukadherin-1. Leukadherin-1 does not modulate Syk activation in NK cells. Leukadherin-1 does not modulate Syk activation in NK cells. Leukadherin-1 (LA1) does not modulate signal transducer and activator of transcription (STAT)-4 phosphorylation. Leukadherin-1 modulates TLR-2 and TLR-7/8-induced monocyte cytokine secretion.
In vivo: Leukadherin-1 decreases macrophage infiltration in the lungs during hyperoxia. Furthermore, treatment with Leukadherin-1 improves alveolarization and angiogenesis and decreases pulmonary vascular remodeling and PH. Targeting leukocyte trafficking using Leukadherin-1, an integrin agonist, is beneficial in preventing lung inflammation and protecting alveolar and vascular structures during hyperoxia.

For the research and scientific use only, not for human use!